WALTHAM, Mass. and DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc ...
Private equity investors are increasingly investing in the drug manufacturing sector thanks to a shift in focus to niche areas and specialized assets, and increased reliance on outsourcing in the last ...
BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of data supporting the broad ability of its IMPACT platform to ...
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced ...
Joe's extensive experience in both small molecule and biologic therapeutics, combined with his recent work in precision medicine, will be invaluable as we advance our neuroimmune platform and pipeline ...
Please replace the release with the following corrected version due to multiple revisions. The updated release reads: RION LAUNCHES RION VET TO TRANSFORM ANIMAL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback